Guided injections for AAV gene transfer to muscle
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Nov 24, 2020
Grant Date -
Aug 31, 2017
app pub date -
Oct 9, 2015
filing date -
Oct 10, 2014
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The disclosure relates to methods for treating subjects with musculoskeletal diseases or with muscle wasting not associated with a musculoskeletal disease by gene transfer with recombinant adeno-associated viruses (rAAV) encoding myostatin inhibitors such as follistatin-344. The rAAV are administered prior to development of diffuse muscle fibrosis in a subject, or the rAAV administration avoids regions of muscle fibrosis in a subject.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully